OWINGS MILLS, Md.--(BUSINESS WIRE)--Univec, Inc. (OTC: UNVC) a specialty pharmaceutical company, announced that its Board of Directors have approved a stock repurchase program. Under the program management is authorized to repurchase up to 100,000,000 shares of the company's stock. The program may be limited or terminated at anytime without prior notice. Repurchase is based on profit and cash flow of the company. Under the stock repurchase program stock may be repurchased by the company from time to time in open market transaction or in privately negotiated transactions as permitted under the applicable rules and regulations.
Univec, Inc. A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals and Transdermal products. The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Smoking Cessation and Drug addiction.
PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.) a subsidiary of Univec promotes and pays for pharmaceutical products though its network of pharmacies. The company through it’s “StarterScript” allows in lieu of a physician sample, a voucher or a co-payment card to be provide to the patient for a trial supply of medication redeemed at any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.
Forward Looking Statements
This document may contain forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec’s business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec’s reports to the General Public and reporting agencies. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec’s reports filed.